WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia

Cancer Genetics

Volumn 208, Issue 5, 2015, Pages 279-287

  Brockway, Sonia ^a,c   Zeleznik Le, Nancy J ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Kinase; Leukemia; MicroRNA; MiR 17 92; WEE1

Indexed keywords

MICRORNA; MICRORNA 17; MICRORNA 17 92; MICRORNA 18A; MICRORNA 19A; MICRORNA 19B; MICRORNA 20A; NUCLEOTIDE; PROTEIN KINASE; PROTEIN WEE1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CELL CYCLE PROTEIN; MIRN17 MICRORNA, HUMAN; MIRN17-92 MICRORNA, HUMAN; MIRN18A MICRORNA, HUMAN; MIRN19 MICRORNA, HUMAN; MIRN20 MICRORNA, HUMAN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; WEE1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE CLUSTER; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HL 60 CELL LINE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HL-60 CELLS; HUMANS; LEUKEMIA; MICRORNAS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES;

EID: 84930576347     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.01.001     Document Type: Article

References (29)

1. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
2. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 2003, 100:9779-9784.
3. Lau N.C., Lim L.P., Weinstein E.G., et al. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
4. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004, 64:3087-3095.
5. Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222.
6. He L., Thomson J.M., Hemann M.T., et al. AmicroRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
7. Dews M., Homayouni A., Yu D., et al. Augmentation of tumor angiogenesis by a myc-activated microRNA cluster. Nat Genet 2006, 38:1060-1065.
8. Xiao C., Srinivasan L., Calado D.P., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
9. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008, 105:15535-15540.
10. Mi S., Li Z., Chen P., et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A 2010, 107:3710-3715.
11. Volinia S., Calin G.A., Liu C.G., et al. AmicroRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
12. McGowan C.H., Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993, 12:75-85.
13. O'Farrell P.H. Triggering the all-or-nothing switch into mitosis. Trends Cell Biol 2001, 11:512-519.
14. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
15. Dreyling M.H., Martinez-Climent J.A., Zheng M., et al. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci U S A 1996, 93:4804-4809.
16. McGowan C.H., Russell P. Cell cycle regulation of human WEE1. EMBO J 1995, 14:2166-2175.
17. Ivanovska I., Ball A.S., Diaz R.L., et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008, 28:2167-2174.
18. Lewis B.P., Shih I.H., Jones-Rhoades M.W., et al. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
19. O'Donnell K.A., Wentzel E.A., Zeller K.I., et al. C-myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
20. Koralov S.B., Muljo S.A., Galler G.R., et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008, 132:860-874.
21. Clancy J.L., Nousch M., Humphreys D.T., et al. Methods to analyze microRNA-mediated control of mRNA translation. Meth Enzymol 2007, 431:83-111.
22. Benes V., Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010, 50:244-249.
23. Hutvagner G., Zamore P.D. AmicroRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
24. Li Y., Vecchiarelli-Federico L.M., Li Y.J., et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 2012, 119:4486-4498.
25. Porter C.C., Kim J., Fosmire S., et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 2012, 26:1266-1276.
26. Qi W., Xie C., Li C., et al. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. JHematol Oncol 2014, 7:53.
27. Chaudhuri L., Vincelette N.D., Koh B.D., et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia exvivo. Haematologica 2014, 99:688-696.
28. Weisberg E., Nonami A., Chen Z., et al. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 2015, 29:27-37.
29. Zhou L., Zhang Y., Chen S., et al. Aregimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 2015, 29:807-818.